Algorithm identifies new potential targets for cancer drugs
Scientists have developed a tool which helps them better understand cancer’s survival tactics and could eventually lead to new treatments for dozens of cancers.
‘Synthetic lethality’, the tactic of blocking pathways that cancer cells rely on, has so far mainly been successful in patients with BRCA-mutated breast, ovarian, prostate and pancreatic cancers.
A new research paper published in the journal Nature Genetics suggests that many more types of cancer may contain similar pairs of ‘synthetic-lethal partner genes’, where cancer cells can survive if one process is disrupted but not two.
A team at The Institute of Cancer Research, London, have developed an algorithm called SYLVER (SYnthetic Lethal Vulnerabilities Exhibiting Reciprocation) designed to review data from more than 9,300 patients.
The researchers noticed that although many cancers have mutations in tumour-suppressor genes they also have higher levels of a different set of genes which must be present for the cancer cells to survive.
Buffering in cancer cells
The findings reveal that although some gene mutations cause cancer, they also make cancer cells ‘addicted’ to a set of new genes.
The study, funded by Cancer Research UK (CRUK), Breast Cancer Now and Walk the Walk, has revealed a list of proteins that could become potential targets for new drugs that would exploit the ‘addictions’ found in cancers.
Dr Syed Haider, Head of the Breast Cancer Data Science Team at The Institute of Cancer Research, London said: “This research tells us how some cancer cells survive despite having faulty mutations in key genes. We’ve learned that when cancers lose a particular tumour-suppressor gene, which usually work to protect our cells from becoming cancerous, they ramp up the activity of back-up processes controlled by other genes to stay alive.
“This is an effect known as buffering. Buffering in cells has been known about for a long time, but our large-scale analysis of over 9,300 patients with different cancers shows that buffering occurs in most cancers and the genes that are increased for the cancer to survive are different, depending upon which tumour suppressor gene is lost. This could mean more potential new treatments for even more types of cancer.”
Diana Spencer, Senior Digital Content Editor, DDW
